Bluejay Diagnostics, Inc. - 8-K Filing
Bluejay Diagnostics reported $3.7 million in cash and a $1.9 million net loss for Q1 2026, consistent with the same period in 2025. The company advanced its Symphony IL-6 test for sepsis monitoring, enrolling 680 of 750 target patients in the SYMON-II clinical trial by May 5, 2026, and resolved manufacturing issues for Symphony cartridges in collaboration with Sanyoseiko Co. Ltd. (Items: 2.02 Results of Operations and Financial Condition, 9.01 Financial Statements and Exhibits)
Tickers: $BJDX